Literature DB >> 17712261

Access to osteoporosis treatment is critically linked to access to dual-energy x-ray absorptiometry testing.

Suzanne M Cadarette1, Monique A M Gignac, Susan B Jaglal, Dorcas E Beaton, Gillian A Hawker.   

Abstract

OBJECTIVE: To determine if inequities in access to osteoporosis investigation [dual-energy x-ray absorptiometry (DXA) testing] and treatment (bisphosphonate, calcitonin, and/or raloxifene) exist among older women in a region with universal health care coverage.
METHODS: Community-dwelling women aged 65-89 years residing within 2 regions of Ontario, Canada were randomly sampled. Data were collected by standardized telephone interview. Potential correlates of DXA testing (verified by physician records), and current treatment were grouped by type as: "predisposing characteristics," "enabling resources," or "need factors" based on hypothesized relationships formulated before data collection. Variables associated with each outcome independent of "need factors" identified inequities in the system.
RESULTS: Of the 871 participants (72% response rate), 55% had been tested by DXA and 20% were receiving treatment. Using multiple variable logistic regression to adjust for need factors, significant inequities in access to DXA testing existed by age, health beliefs, education, income, use of preventive health services, region, and provider sex. DXA testing mediated access to treatment; 34% of those having had a DXA were treated compared with 2% of those who did not. Among women with osteoporosis, correctly reporting that their DXA test indicated osteoporosis and higher perceived benefits of taking pharmacological agents for osteoporosis were associated with treatment.
CONCLUSIONS: Significant inequities in access to fracture prevention exist in a region with universal health care coverage. Improved access to DXA and better communication to patients of both their DXA results and the benefits of treatment has the potential to reduce the burden of osteoporosis.

Entities:  

Mesh:

Year:  2007        PMID: 17712261     DOI: 10.1097/MLR.0b013e318054689f

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  22 in total

1.  The effect modification of supplemental insurance on the relationship between race and bone mineral density screening in female Medicare beneficiaries.

Authors:  Ji Won Yoo; Shunichi Nakagawa; Sulgi Kim
Journal:  J Immigr Minor Health       Date:  2012-12

2.  Hip fracture and other predictors of anti-osteoporosis drug use in Norway.

Authors:  H M Devold; A J Søgaard; A Tverdal; J A Falch; K Furu; H E Meyer
Journal:  Osteoporos Int       Date:  2012-07-10       Impact factor: 4.507

3.  The post-fracture care gap among Canadian First Nations peoples: a retrospective cohort study.

Authors:  W D Leslie; S L Brennan; H J Prior; L M Lix; C Metge; B Elias
Journal:  Osteoporos Int       Date:  2012-01-03       Impact factor: 4.507

4.  Osteoporosis pharmacotherapy following bone densitometry: importance of patient beliefs and understanding of DXA results.

Authors:  D Brask-Lindemann; S M Cadarette; P Eskildsen; B Abrahamsen
Journal:  Osteoporos Int       Date:  2010-08-04       Impact factor: 4.507

Review 5.  Quality health care gaps in osteoporosis: how can patients, providers, and the health system do a better job?

Authors:  Gim Gee Teng; Jeffrey R Curtis; Kenneth G Saag
Journal:  Curr Osteoporos Rep       Date:  2009-03       Impact factor: 5.096

6.  Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture.

Authors:  Suzanne M Cadarette; Jeffrey N Katz; M Alan Brookhart; Til Stürmer; Margaret R Stedman; Daniel H Solomon
Journal:  Ann Intern Med       Date:  2008-05-06       Impact factor: 25.391

7.  Critical impact of patient knowledge and bone density testing on starting osteoporosis treatment after fragility fracture: secondary analyses from two controlled trials.

Authors:  S R Majumdar; F A McAlister; J A Johnson; D L Weir; D Bellerose; D A Hanley; A S Russell; B H Rowe
Journal:  Osteoporos Int       Date:  2014-05-07       Impact factor: 4.507

8.  Patient and physician predictors of post-fracture osteoporosis management.

Authors:  Adam E Block; Daniel H Solomon; Suzanne M Cadarette; Helen Mogun; Niteesh K Choudhry
Journal:  J Gen Intern Med       Date:  2008-06-27       Impact factor: 5.128

9.  A multifaceted intervention to improve treatment of osteoporosis in postmenopausal women with wrist fractures: a cluster randomized trial.

Authors:  A Cranney; M Lam; L Ruhland; R Brison; M Godwin; M M Harrison; M B Harrison; T Anastassiades; J M Grimshaw; I D Graham
Journal:  Osteoporos Int       Date:  2008-07-16       Impact factor: 4.507

10.  Measuring patient perceptions about osteoporosis pharmacotherapy.

Authors:  Suzanne M Cadarette; Monique A M Gignac; Susan B Jaglal; Dorcas E Beaton; Gillian A Hawker
Journal:  BMC Res Notes       Date:  2009-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.